Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease

Clin Chem. 2024 Oct 3;70(10):1298. doi: 10.1093/clinchem/hvae038.
No abstract available

MeSH terms

  • Anemia, Sickle Cell* / genetics
  • Anemia, Sickle Cell* / therapy
  • CRISPR-Cas Systems*
  • Gene Editing* / methods
  • Genetic Therapy* / methods
  • Humans
  • United States
  • United States Food and Drug Administration